These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

58 related articles for article (PubMed ID: 17493314)

  • 1. Modeling payback from research into the efficacy of left-ventricular assist devices as destination therapy.
    Girling AJ; Freeman G; Gordon JP; Poole-Wilson P; Scott DA; Lilford RJ
    Int J Technol Assess Health Care; 2007; 23(2):269-77. PubMed ID: 17493314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of continuous-flow left ventricular assist devices.
    Neyt M; Van den Bruel A; Smit Y; De Jonge N; Erasmus M; Van Dijk D; Vlayen J
    Int J Technol Assess Health Care; 2013 Jul; 29(3):254-60. PubMed ID: 23763844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of the implantable HeartMate II left ventricular assist device for patients awaiting heart transplantation.
    Moreno SG; Novielli N; Cooper NJ
    J Heart Lung Transplant; 2012 May; 31(5):450-8. PubMed ID: 22115674
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and cost-effectiveness of left ventricular assist devices as destination therapy for people with end-stage heart failure: a systematic review and economic evaluation.
    Clegg AJ; Scott DA; Loveman E; Colquitt J; Royle P; Bryant J
    Int J Technol Assess Health Care; 2007; 23(2):261-8. PubMed ID: 17493313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improving outcomes with long-term "destination" therapy using left ventricular assist devices.
    Long JW; Healy AH; Rasmusson BY; Cowley CG; Nelson KE; Kfoury AG; Clayson SE; Reid BB; Moore SA; Blank DU; Renlund DG
    J Thorac Cardiovasc Surg; 2008 Jun; 135(6):1353-60; discussion 1360-1. PubMed ID: 18544385
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness analysis of continuous-flow left ventricular assist devices as destination therapy.
    Rogers JG; Bostic RR; Tong KB; Adamson R; Russo M; Slaughter MS
    Circ Heart Fail; 2012 Jan; 5(1):10-6. PubMed ID: 22052901
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes of left ventricular assist device implantation as destination therapy in the post-REMATCH era: implications for patient selection.
    Lietz K; Long JW; Kfoury AG; Slaughter MS; Silver MA; Milano CA; Rogers JG; Naka Y; Mancini D; Miller LW
    Circulation; 2007 Jul; 116(5):497-505. PubMed ID: 17638928
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Left ventricular assist device as destination for patients undergoing intravenous inotropic therapy: a subset analysis from REMATCH (Randomized Evaluation of Mechanical Assistance in Treatment of Chronic Heart Failure).
    Stevenson LW; Miller LW; Desvigne-Nickens P; Ascheim DD; Parides MK; Renlund DG; Oren RM; Krueger SK; Costanzo MR; Wann LS; Levitan RG; Mancini D;
    Circulation; 2004 Aug; 110(8):975-81. PubMed ID: 15313942
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative survival and cost-effectiveness of advanced therapies for end-stage heart failure.
    Long EF; Swain GW; Mangi AA
    Circ Heart Fail; 2014 May; 7(3):470-8. PubMed ID: 24563450
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Left ventricular device as destination therapy: are we there yet?
    Badiwala MV; Rao V
    Curr Opin Cardiol; 2009 Mar; 24(2):184-9. PubMed ID: 19532106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Left ventricular assist devices as destination therapy: a new look at survival.
    Park SJ; Tector A; Piccioni W; Raines E; Gelijns A; Moskowitz A; Rose E; Holman W; Furukawa S; Frazier OH; Dembitsky W
    J Thorac Cardiovasc Surg; 2005 Jan; 129(1):9-17. PubMed ID: 15632819
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of ventricular assist device use in the United Kingdom: results from the evaluation of ventricular assist device programme in the UK (EVAD-UK).
    Sharples LD; Dyer M; Cafferty F; Demiris N; Freeman C; Banner NR; Large SR; Tsui S; Caine N; Buxton M
    J Heart Lung Transplant; 2006 Nov; 25(11):1336-43. PubMed ID: 17097498
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of left ventricular-assist devices in end-stage heart failure.
    Hutchinson J; Scott DA; Clegg AJ; Loveman E; Royle P; Bryant J; Colquitt JL
    Expert Rev Cardiovasc Ther; 2008 Feb; 6(2):175-85. PubMed ID: 18248272
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hospital costs for left ventricular assist devices for destination therapy: lower costs for implantation in the post-REMATCH era.
    Miller LW; Nelson KE; Bostic RR; Tong K; Slaughter MS; Long JW
    J Heart Lung Transplant; 2006 Jul; 25(7):778-84. PubMed ID: 16818120
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Left ventricular assist devices as permanent heart failure therapy: the price of progress.
    Oz MC; Gelijns AC; Miller L; Wang C; Nickens P; Arons R; Aaronson K; Richenbacher W; van Meter C; Nelson K; Weinberg A; Watson J; Rose EA; Moskowitz AJ
    Ann Surg; 2003 Oct; 238(4):577-83; discussion 583-5. PubMed ID: 14530729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Can the Seattle heart failure model be used to risk-stratify heart failure patients for potential left ventricular assist device therapy?
    Levy WC; Mozaffarian D; Linker DT; Farrar DJ; Miller LW;
    J Heart Lung Transplant; 2009 Mar; 28(3):231-6. PubMed ID: 19285613
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Post-cardiac transplant survival after support with a continuous-flow left ventricular assist device: impact of duration of left ventricular assist device support and other variables.
    John R; Pagani FD; Naka Y; Boyle A; Conte JV; Russell SD; Klodell CT; Milano CA; Rogers J; Farrar DJ; Frazier OH
    J Thorac Cardiovasc Surg; 2010 Jul; 140(1):174-81. PubMed ID: 20447659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes after implantation of partial-support left ventricular assist devices in inotropic-dependent patients: Do we still need full-support assist devices?
    Sabashnikov A; Popov AF; Bowles CT; Mohite PN; Weymann A; Hards R; Hedger M; Wittwer T; Wippermann J; Wahlers T; Schoendube FA; Simon AR
    J Thorac Cardiovasc Surg; 2014 Sep; 148(3):1115-21; discussion 1021-2. PubMed ID: 25129605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved survival and decreasing incidence of adverse events with the HeartMate II left ventricular assist device as bridge-to-transplant therapy.
    John R; Kamdar F; Liao K; Colvin-Adams M; Boyle A; Joyce L
    Ann Thorac Surg; 2008 Oct; 86(4):1227-34; discussion 1234-5. PubMed ID: 18805167
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Destination therapy with left ventricular assist devices: for whom and when?
    Porepa LF; Starling RC
    Can J Cardiol; 2014 Mar; 30(3):296-303. PubMed ID: 24565254
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.